异氟醚下调MYC表达抑制高级别脑胶质瘤细胞增殖转移

目的 探究异氟醚对高级别脑胶质瘤细胞MYC基因表达及细胞增殖转移能力的影响。方法 分别采用含2%异氟醚的气体环境及常规气体环境（5% CO₂）培养对数生长期的人脑胶质瘤细胞系SHG-44 6 h，作为异氟醚组及对照组；CCK-8实验检测两组细胞气体暴露完成后0、24、48、72 h相对增殖能力；Transwell侵袭及迁移实验检测两组细胞侵袭及迁移能力；Western Blotting检测两组细胞C-Myc及N-Myc的蛋白表达。结果 异氟醚组细胞于暴露完成后48、72 h时增殖能力较对照组细胞显著下调，差异具有统计学意义（P<0.01）；异氟醚组穿透基质胶的侵袭细胞数、穿过微孔的迁移细胞数均较对照组显著减少，差异均具有统计学意义（P<0.01、0.001）；异氟醚组C-Myc及N-Myc的表达较对照组均显著下调，差异具有统计学意义（P<0.01）。结论 异氟醚可通过下调C-Myc及N-Myc基因的表达，抑制人高级别脑胶质瘤细胞的增殖转移。

Isoflurane inhibits proliferation and metastasis of high grade glioma cells by down-regulating expression of MYC gene

Objective To investigate the effect of isoflurane on the expression of MYC gene and cell proliferation and metastasis in high grade glioma cells. Methods The gas environment containing 2% isoflurane and conventional gas environment (5% CO₂)for the cultivation of human glioma cell line SHG-44 6 h in logarithmic growth phase, as the isoflurane group and the control group. CCK-8 assay detected the relative proliferation ability of two groups of cells in 0, 24, 48, and 72 h. Transwell invasion and migration assay detected invasion and migration ability of two groups. Western blotting assay detected the expression of C-Myc and N-Myc in two groups. Results The proliferation ability of isoflurane group was decreased compared to control group in 48 and 72 h, and the difference was statistically significant (P<0.01). The number of invasion cells through Matrigel in isoflurane group was significantly reduced compared to control group, and the number of migrating cells through chamber in isoflurane group was significantly reduced compared to the control group cells, the difference was statistically significant (P<0.01 and 0.001). The expression of C-Myc and N-Myc in isoflurane group were significantly reduced compared to the control group, the difference was statistically significant (P<0.01). Conclusion Isoflurane can inhibit the proliferation and metastasis of human high grade glioma cells by down-regulating the expression of C-Myc and N-Myc genes, and has potential clinical value.